Radiopharm Theranostics (NASDAQ:RADX) had its price target lowered by analysts at B. Riley from $15.00 to $13.00. They now have a "buy" rating on the stock.
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs